Assoc. Prof. PharmDr. Jaroslav Roh, Ph.D.

Education, positions, international experiences

• 2019-2022 - Head of the Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University
• 2018-2022 - Vice-Dean for Scientific Activity, Doctoral Studies and Technology Transfer, Faculty of Pharmacy in Hradec Králové, Charles University
• since 2018 - Associate Professor at the Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University
• 2013 - three months research stay at the University of Bath (UK) in the group of Dr. Ian M. Eggleston
• 2008 - 2017 assistant professor at the Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University
• 2007 - three month traineeship at State Technological Institute in St.Petersburg, (Russian federation) - supervisor Prof. G. I. Koldobskii
• 2006-2010 - Doctoral study of Bioorganic chemistry at the Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University in Prague
• 2001-2006 - Master’s study of pharmacy at Faculty of Pharmacy in Hradec Králové, Charles University in Prague

Research interests

• Structure-activity relationships of potential antitubercular agents
• Structure-activity relationships of dexrazoxane analogues
• (chemistry of nitrogen heterocycles)
• (synthesis of hydrazone and thiosemicabazone-based iron chelators)

Teaching and popularization of science:

• 2019/2020 Guarantor of subjects
  M.Sc. study program Pharmacy: General and Inorganic Chemistry; Diploma Thesis Elaboration I; Exercises in General Chemistry; Constitution of Organic Compounds; Research Project I; Research Project II
  B.Sc. study program Medical Bioanalytics: General and Inorganic Chemistry, Exercises in General Chemistry; Research Project
• since 2008:
  • supervisor of >20 M.Sc. students (diploma theses);
  • co-supervisor of one Ph.D. students (graduated), supervisor of four Ph.D. students (one graduated)
  • lecturer of General and Inorganic Chemistry study courses for B.Sc. and M.Sc. students (Pharmacy and Medical Bioanalytics), Chemical Laboratory Technique for M.Sc. students (Pharmacy), Charles University, Faculty of Pharmacy in Hradec Králové
• 2014 - 2019 - organizer of “Postgraduate and Postdoc conference” at the Faculty of Pharmacy
• Presentations “Science at the Faculty of Pharmacy” for Secondary schools

Scientific Grants

Ongoing

• since 2022 - Member of the project National Institute of virology and bacteriology - NIVB (Programme EXCELES, ID Project No. LX22NPO5103) funded by the European Union - Next Generation EU.

• since 2021 - Co-Principal Investigator of Czech Health Research Council project NU21-05-00446 From hit-to-lead candidate – development of novel agents to combat tuberculosis

• since 2021 -  co-worker of Czech Science Foundation project 21-16195S - Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta

• since 2019 – senior researcher in EU-funded project Pre-application research into innovative medicines and medical technologies (InoMed), reg. no. CZ.02.1.01/0.0/0.0/18_069/0010046

Finished projects

• 2019 - 2022 - senior researcher in EU-funded project Efficiency and Safety Improvement of Current Drugs and Nutraceuticals: Advanced Methods – New Challenges (EFSA–CDN), reg. no. CZ.02.1.01/0.0/0.0/16_019/0000841

• 2018-2020 - co-worker of Czech science foundation project 18-08169S - Study of individual topoisomerase II isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines

• 2014-2016 - co-worker of finished Czech science foundation project 14-08423S - Structure-activity-toxicity relationships studies in the group of small-molecule compounds with antimycobacterial activity - corresponding author of all resulting publications

• 2014-2016 - Co-Principal and later Principal Investigator of finished Czech science foundation project 14-02165P

• Co-worker of other 5 finished Czech science foundation projects:
  2013-2017 - 13-15008S - New potential cardioprotective agents: Study of structure-activity relationships in various types of myocardial injury
  2013-2017 - 13-23891S - Lipid membrane models – a new tool for studying pathophysiology of skin diseases at a molecular level
  GACR 203/07/1302; GACR 207/10/2048; GACR 207/11/0365

• 2012-2017 - co-worker of Charles University Research Centre (UNCE 204019/304019/2012): Centre for the Study of Toxic and Protective Effects of Drugs on Cardiovascular System

• 2012 - 2015 - co-worker in two EU-funded projects “Pre-seed activities of CU out of Prague“, reg. no. CZ.1.05/3.1.00/13.0284 and "Pre-seed activities of CU out of Prague II", reg. no. CZ.1.05/3.1.00/14.0299.

Awards

• 2018 - winner of Alfred Bader’s Prize in bioorganic and bioinorganic chemistry
• 2009 - Medal of the Faculty of Pharmacy
• 2006 - Award of the Dean of the Faculty of Pharmacy in Hradec Králové, Charles University

Professional Memberships

• Czech Chemical Society

Publications

author and co-author of 50 papers in international peer-reviewed journals, Σ IF > 212, >1030 citations (WoS; excluding self-citations); H-index: 19 (WoS).

• E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF₂₀₂₁ = 10.447) (D_AIS1)
• A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh*. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF₂₀₂₁ = 8.039) (D_AIS1)
• G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh*. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019, 62, 8115-8139. (IF₂₀₁₉ = 6.205) (D1)
• J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF₂₀₁₇ = 4.816) (Q1)
• G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF₂₀₁₇ = 4.816) (Q1)
• G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF₂₀₁₆ = 6.259) (D1)
• G. Karabanovich, J. Roh,* T. Smutný, J. Něměcek, P. Vicherek, J. Stolaříková, M. Vejsová, I. Dufková, K. Vávrová, P. Pávek, V. Klimešová, A. Hrabálek. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Eur. J. Med. Chem. 2014, 82, 324-340. (IF₂₀₁₄ = 3.447) (Q1)

Complete list

Patents and patent applications

PCT patent applications

1. WO2021/144746 A1 (PCT/IB2021/050285). Roh J., Štěrba M., Šimůnek T., Štěrbová P., Karabanovich G., Jirkovská A., Jirkovský E., Bavlovič Piskáčková H., Kubeš J., Jansová H., Kollárová P. Use of ICRF-193 derivatives and pharmaceutical preparations containing thereof for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs. 

2. WO2016/091228 A1 (PCT/CZ2015/000126). Roh J., Němeček J., Hrabálek A., Klimesova V., Karabanovich G., Pavek P., Sychra P. Substituted phenyltetrazole, its use and pharmaceutical preparation containing the same.

3. WO2014/161516 (PCT/CZ2013/000131). Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Oxa- and thia-diazoles useful in the treatment of Tuberculosis.

Czech patents

1. CZ 305622 B6. Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Substituovaný tetrazol, jeho použití a farmaceutický přípravek ho obsahující.

2. CZ 305680 B6. Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Substituovaný diazol, jeho použití a farmaceutický přípravek ho obsahující.

3. CZ 306408 B6. Karabanovich G., Roh J., Hrabálek A., Klimešová V., Pávek P.: Dinitrofenyl oxadiazol a triazol, jeho použití a farmaceutický přípravek ho obsahující.

4. CZ 306245 B6. Roh J., Němeček J., Hrabálek A., Klimešová V., Karabanovich G., Pávek P., Sychra P.: Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující.

5. CZ 306321 B6. Němeček J., Roh J., Hrabálek A., Klimešová V., Karabanovich G., Pávek P.: Substituovaný dinitrofenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující.

6. CZ 307936 B6. Čonka P., Hrabálek A., Karabanovich G., Němeček J., Klimešová V., Valášková L., Roh. J.: Substituovaný nitrobenzyltetrazol, jeho použití a farmaceutický přípravek ho obsahující.

7. CZ 308557​ B6. Roh J., Karabanovich G., Pavek P., Hrabálek A.: Substituovaný 1,2,4-oxadiazol, jeho použití a farmaceutický přípravek ho obsahující (Substituted 1,2,4-oxadiazole, its use and pharmaceutical preparation containing the same). bought by Svenox Pharmaceuticals LLC

8. CZ 309069 B6. Roh J., Štěrba M., Šimůnek T., Štěrbová P., Karabanovich G., Jirkovská A., Jirkovský E., Bavlovič Piskáčková H., Kubeš J., Jansová H., Kollárová P.: Použití derivátů sloučeniny ICRF-193 a farmaceutický přípravek k prevenci chronické kumulativní kardiotoxicity způsobené terapií antracyklinovými protinádorovými léčivy